ESC 2016 - PACE-CME

1-16 of 19

Extra work of checking device data weekly does not translate into benefit for HF patient
Extra work of checking device data weekly does not translate into benefit for HF patient
ESC 2016
Extra work of checking device data weekly does not translate into benefit for HF patient
Martin Cowie, MD
- Martin Cowie, MD
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
ESC 2016
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
Dr. Brian Ference
- Dr. Brian Ference
Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
Prof. Mariell Jessup
- Prof. Mariell Jessup
Epigenetics: A closer look at BET inhibition
Epigenetics: A closer look at BET inhibition
ESC 2016
Epigenetics: A closer look at BET inhibition
No indication for difference in efficacy between potent platelet inhibitors after PCI
No indication for difference in efficacy between potent platelet inhibitors after PCI
ESC 2016
No indication for difference in efficacy between potent platelet inhibitors after PCI
Steen Dalby Kristensen, MD
- Steen Dalby Kristensen, MD
Iron deficiency in the new HF guidelines
Iron deficiency in the new HF guidelines
ESC 2016
Iron deficiency in the new HF guidelines
Peter van der Meer, MD
- Peter van der Meer, MD
Heart failure news at the ESC
Heart failure news at the ESC
ESC 2016
Heart failure news at the ESC
Frank Ruschitzka, MD
- Frank Ruschitzka, MD
To SPRINT or not to SPRINT to a lower blood pressure target?
To SPRINT or not to SPRINT to a lower blood pressure target?
CSI 2016 ESC
To SPRINT or not to SPRINT to a lower blood pressure target?
Targeting residual inflammatory risk as a strategy to lower CV risk
Targeting residual inflammatory risk as a strategy to lower CV risk
CSI 2016 ESC
Targeting residual inflammatory risk as a strategy to lower CV risk
prof. Paul Ridker, MD
- prof. Paul Ridker, MD
Beyond statins: The role of ezetimibe in targeting residual risk
Beyond statins: The role of ezetimibe in targeting residual risk
ESC 2016
Beyond statins: The role of ezetimibe in targeting residual risk
Chris Packard, MD
- Chris Packard, MD
Interim results of new device for treatment resistant hypertension
Interim results of new device for treatment resistant hypertension
CSI 2016 ESC
Interim results of new device for treatment resistant hypertension
Dr. Wilko Spiering
- Dr. Wilko Spiering
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
CSI 2016 ESC
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
Prof. Silvio E Inzucchi
- Prof. Silvio E Inzucchi
Would lower than the current ApoB targets be more useful for clinical decision-making?
Would lower than the current ApoB targets be more useful for clinical decision-making?
CSI 2016 ESC
Would lower than the current ApoB targets be more useful for clinical decision-making?
Seth Shay Martin, MD
- Seth Shay Martin, MD
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
ESC 2016
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
Erik Stroes, MD
- Erik Stroes, MD
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
ESC 2016
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
John Kastelein, MD
- John Kastelein, MD
Inflammation as potential target for therapy to target residual risk post ACS
Inflammation as potential target for therapy to target residual risk post ACS
ESC 2016
Inflammation as potential target for therapy to target residual risk post ACS
Paul M Ridker, MD
- Paul M Ridker, MD

Prev
1
2
Next

1/2